The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,812.50
Bid: 1,812.00
Ask: 1,813.00
Change: 2.50 (0.14%)
Spread: 1.00 (0.055%)
Open: 1,811.00
High: 1,814.50
Low: 1,805.00
Prev. Close: 1,810.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Limited protection of GSK's malaria vaccine dwindles in 7 years

Wed, 29th Jun 2016 21:00

* Study raises questions over deployment of vaccine

* Mosquirix not perfect but still has life-saving potential

* Could provide springboard for second-generation vaccines

By Kate Kelland, Health and Science Correspondent

LONDON, June 29 (Reuters) - The world's first malariavaccine, developed by GlaxoSmithKline, provides someprotection after three doses but its effect dwindles to almostnothing after seven years, scientists said on Wednesday.

Publishing a long-term study of the vaccine - called RTS,Sor Mosquirix and designed for children in Africa where thedisease claims most of its victims - researchers said thedecline in its efficacy over time is fastest in children livingin areas with higher than average rates of malaria.

This raises questions about whether Mosquirix can play ameaningful role in fighting malaria, they said, and suggests afour-dose schedule would be needed if it were used.

"The results suggest that the implementation of RTS,S willneed to be considered carefully and in a way that takes intoaccount different levels of malaria exposure," said Mike Turner,head of infections at the Wellcome Trust global health charitywhich helped fund the research.

He added that while the vaccine "isn't perfect", it stillhas the potential to save lives "and will provide an importantspringboard for improved second-generation vaccines".

Malaria, a mosquito-borne parasitic disease, kills around400,000 people a year, the vast majority of them children andbabies in sub-Saharan Africa. World Health Organization (WHO)data show there are around 200 million malaria cases a year.

Hopes that GSK's shot could wipe out malaria were dashedwhen trial data in 2011 and 2012 showed that Mosquirix reducedmalaria episodes in babies aged six to 12 weeks by 27 percent,and by about 46 percent in children aged five to 17 months.

Despite its limited efficacy, Mosquirix last year became thefirst ever malaria vaccine to win regulatory approval, when theEuropean Medicines Agency gave it a green light. The WHO,meanwhile, has said that Mosquirix is promising in its potentialto reduce cases of malaria, but should be deployed only on apilot basis before any wide-scale use.

For this latest study, published in the New England Journalof Medicine, researchers at the KEMRI-Wellcome Trust researchprogramme in Kilifi, Kenya, followed 447 children who hadreceived three doses of either Mosquirix or a control vaccinewhen they were 5 to 17 months old. After seven years, there were312 children still involved in the study.

The results showed that during the first year, the risk ofgetting malaria in the vaccinated children was 35.9 percent lessthan in the control group, but after seven years this differencefell to 4.4 percent.

After five years, in children exposed to higher than averagerates of malaria, there were more cases (1,002) in thevaccinated group compared with the control group (992).

Philip Bejon, director of the KEMRI programme, said this"rebound" effect is thought to be caused by the vaccinatedchildren developing their natural immunity against malaria moreslowly than unvaccinated children.

GSK, which has been working on Mosquirix for 30 years, haspromised it will make no profit from it, pricing it at the costof manufacture plus a 5 percent margin which it will reinvest inresearch on malaria and other neglected tropical diseases. Theshot also contains an adjuvant, or booster, made by the U.S.biotech company Agenus. (Reporting by Kate Kelland)

More News
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.